Combination treatment boosts bladder cancer survival rate
Patients with locally advanced bladder cancer have more than a fighting chance for survival with neoadjuvant chemotherapy, which has been found to provide a longer life in patients compared with the standard treatment of surgery alone, according to an 11-year study published in the New England Journal of Medicine (2003; 349:859-66).
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.